Monoclonal antibodies in severe asthma: outcomes from real-world data

Monoclonal antibodies in severe asthma: outcomes from real-world data

BackgroundUncontrolled severe asthma represents a substantial clinical and economic burden, particularly in patients with comorbidities and poor response to high-dose inhaled corticosteroids. Monoclonal antibodies targeting type 2 (T2) inflammation have become key therapeutic options, but their real...

Full description

Saved in:
Bibliographic Details
Main Authors: Silvia del-Barrio-Buesa, Álvaro Narrillos-Moraza, Julia García-de-Pedro, Francisco Javier de-Castro-Martínez, María Esther Durán-García, Vicente Escudero-Vilaplana, Elena Lobato-Matilla, Rosa Romero-Jimenez, Esther Chamorro-de-Vega, Paula Ruiz-Briones, Félix Jesús Garcia-Moreno, María Martín-Bartolomé, Ana Herranz, María Sanjurjo
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Medicine
Subjects:
benralizumab
mepolizumab
monoclonal antibody
omalizumab
real-world data
reslizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1635688/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2025.1635688/full

Similar Items